What is the first-line antibiotic treatment for enteric (typhoid) fever in an adult without known drug allergies?

First-Line Antibiotic for Enteric Fever

The first-line antibiotic choice for enteric fever must be guided by local resistance patterns and geographic origin, but in the current era of widespread fluoroquinolone resistance—particularly from South Asia—azithromycin or ceftriaxone should be prioritized over fluoroquinolones for empiric therapy.

Critical Decision Algorithm

Step 1: Determine Geographic Origin and Resistance Pattern

If patient acquired infection in South Asia (India, Pakistan, Bangladesh, Nepal):

• Use azithromycin or ceftriaxone as first-line 1
• Fluoroquinolones (ciprofloxacin) should NOT be used due to widespread resistance 1, 2
• Recent data from India shows 63.3% fluoroquinolone resistance while maintaining 100% susceptibility to ceftriaxone and azithromycin 2

If patient acquired infection outside South Asia with known fluoroquinolone-sensitive strains:

• Fluoroquinolones (ciprofloxacin, ofloxacin, gatifloxacin) remain an option 3
• However, this scenario is increasingly rare

Step 2: Select Specific Agent Based on Evidence

Azithromycin is superior to fluoroquinolones based on the highest quality comparative data:

• Lower clinical failure rate (OR 0.48,95% CI 0.26-0.89) 3
• Shorter hospital stay by approximately 1 day 3
• Dramatically lower relapse rate compared to ceftriaxone (OR 0.09,95% CI 0.01-0.70) 3

Ceftriaxone as alternative first-line:

• 100% susceptibility maintained even in high-resistance settings 2
• Particularly important for extensively drug-resistant (XDR) typhoid from Pakistan 1
• May have higher relapse rates than azithromycin but remains highly effective 3

Critical Resistance Considerations

The Fluoroquinolone Problem

The WHO 2012 guidelines recommending fluoroquinolones as first-line 3 are outdated and no longer applicable in most endemic regions:

• A 2016 RCT comparing gatifloxacin versus ceftriaxone was stopped early due to emergence of high-level ciprofloxacin and gatifloxacin resistance 3
• In culture-confirmed cases from that trial, ceftriaxone had significantly lower failure rates (HR 0.24,95% CI 0.08-0.73) 3
• Recent 2026 data confirms persistent 63.3% fluoroquinolone resistance in India 2

Preserved Susceptibility

All recent isolates remain susceptible to:

• Ceftriaxone (100%) 2
• Azithromycin (100%) 2
• Carbapenems (100%) 2
• Surprisingly, conventional agents (chloramphenicol, cotrimoxazole) show re-emerging susceptibility 2

Practical Treatment Recommendations

For empiric therapy in adults without known drug allergies:

1. First choice: Azithromycin (oral, outpatient-appropriate)

   • Superior efficacy data versus both fluoroquinolones and ceftriaxone
   • Lowest relapse rates
   • Oral administration facilitates outpatient management

2. Alternative first choice: Ceftriaxone (parenteral)

   • When azithromycin unavailable or patient requires hospitalization
   • Extensively drug-resistant typhoid
   • Severe illness requiring IV therapy

3. Reserve fluoroquinolones only for:

   • Documented susceptibility by culture
   • Infections acquired outside South Asia with known local susceptibility patterns
   • This scenario is increasingly uncommon

Common Pitfalls to Avoid

Do not reflexively use fluoroquinolones based on older guidelines—resistance has fundamentally changed the treatment landscape since 2012-2016 3, 1, 2

Do not assume susceptibility patterns from 5+ years ago apply—the emergence of XDR typhoid in Pakistan and widespread fluoroquinolone resistance in South Asia represents a paradigm shift 1, 4

Do not delay treatment waiting for culture results in endemic settings—blood culture sensitivity is poor, and empiric therapy based on local resistance patterns is standard practice 1, 4

For XDR typhoid (resistant to fluoroquinolones, third-generation cephalosporins, and conventional agents), combination therapy with azithromycin plus meropenem may be required 4